
发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
OBJECTIVE:Women with pre-eclampsia have elevated circulating levels of soluble fms-like tyrosine kinase-1 (sFlt-1). Statins can reduce sFlt-1 from cultured cells and improve pregnancy outcome in animals with a pre-eclampsia-like syndrome. We investigated the effect of pravastatin on plasma sFlt-1 levels during pre-eclampsia. DESIGN:Blinded (clinician and participant), proof of principle, placebo-controlled trial. SETTING:Fifteen UK maternity units. POPULATION:We used a minimisation algorithm to assign 62 women with early-onset pre-eclampsia (24+0 -31+6 weeks of gestation) to receive pravastatin 40 mg daily (n = 30) or matched placebo (n = 32), from randomisation to childbirth. PRIMARY OUTCOME:Difference in mean plasma sFlt-1 levels over the first 3 days following randomisation. RESULTS:The difference in the mean maternal plasma sFlt-1 levels over the first 3 days after randomisation between the pravastatin (n = 27) and placebo (n = 29) groups was 292 pg/ml (95% CI -1175 to 592; P = 0.5), and over days 1-14 was 48 pg/ml (95% CI -1009 to 913; P = 0.9). Women who received pravastatin had a similar length of pregnancy following randomisation compared with those who received placebo (hazard ratio 0.84; 95% CI 0.50-1.40; P = 0.6). The median time from randomisation to childbirth was 9 days (interquartile range [IQR] 5-14 days) for the pravastatin group and 7 days (IQR 4-11 days) for the placebo group. There were three perinatal deaths in the placebo-treated group and no deaths or serious adverse events attributable to pravastatin. CONCLUSIONS:We found no evidence that pravastatin lowered maternal plasma sFlt-1 levels once early-onset pre-eclampsia had developed. Pravastatin appears to have no adverse perinatal effects. TWEETABLE ABSTRACT:Pravastatin does not improve maternal plasma sFlt-1 or placental growth factor levels following a diagnosis of early preterm pre-eclampsia #clinicaltrial finds.
展开更多
最新影响因子:7.331 | 期刊ISSN:1470-0328 | CiteScore:1.89 |
出版周期:Monthly | 是否OA:YES | 出版年份:2000 |
自引率:5.50% | 研究方向:医学-妇产科学 |
出版地区:ENGLAND |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
The British Journal of Obstetrics and Gynaecology (BJOG) is an editorially independent publication owned by the Royal College of Obstetricians and Gynaecologists. The Journal publishes original, peer reviewed work in all areas of obstetrics and gynaecology, including contraception, uro-gynaecology, fertility, oncology and clinical practice. Its aim is to publish the highest quality of medical research in women''s health worldwide.
《英国妇产科杂志》(BJOG)是皇家妇产科学院拥有的独立编辑刊物。该杂志发表了最初的,同行评审的工作,在所有领域的产科和妇科,包括避孕,泌尿妇科,生育,肿瘤和临床实践。它的目标是在世界范围内出版关于妇女健康的最高质量的医学研究。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
OBSTETRICS & GYNECOLOGY (妇产科学) 2区 |
6/82 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
201 | 154 | 47 |
引文计数(2018)
文献(2015-2017)
2937次引用
1557篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Obstetrics and Gynecology
|
#51/168
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
14年经验沉淀,实体公司
运营
liting7111
liting7111
研究方向:医药科学 生殖系统 围生医学 新生儿 分娩 产褥
审稿时间: 1个月内
liting7111
研究方向:妇产科
审稿时间: 6个月内 接受率: 比较困难(25%命中)
影响因子:3.413
ISSN:1546-0096
研究方向:PEDIATRICS-RHEUMATOLOGY
影响因子:2.858
ISSN:0961-2033
研究方向:医学-风湿病学
影响因子:7.046
ISSN:1462-0324
研究方向:医学-风湿病学
影响因子:5.263
ISSN:1297-319X
研究方向:医学-风湿病学
影响因子:2.862
ISSN:1439-7595
研究方向:RHEUMATOLOGY-
影响因子:3.65
ISSN:0770-3198
研究方向:医学-风湿病学
影响因子:0.159
ISSN:0341-051X
研究方向:医学-风湿病学
影响因子:5.346
ISSN:0315-162X
研究方向:医学-风湿病学
影响因子:15.483
ISSN:2326-5191
研究方向:RHEUMATOLOGY-
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY 投稿经验
(由下方点评分析获得,3人参与,13808人阅读)